Huseyin Naci


Dr. Huseyin Naci is a Research Fellow within LSE Health.

Huseyin’s academic interests include research design, comparative effectiveness research, drug regulation, and health policy evaluation. His methodological research focuses on the strengths and weaknesses of study designs in determining the benefits and harms of health care interventions and policies. He is particularly interested in the application of evidence generated from randomized trials, observational studies, and network meta-analyses to decision-making in health policy and clinical practice.

Huseyin’s policy-relevant research focuses on the unintended consequences of health policies; market entry requirements for new health technologies; economic access to medications; and the role of health care professionals in caring for individuals with multiple chronic conditions. He is also interested in research that has implications for clinical practice: using widely popular cholesterol-lowering statins as a case study, his recent work| evaluated the comparative clinical benefits and harms of individual statins for the prevention of coronary heart disease.

Prior to starting his research at LSE Health, Huseyin conducted research in the areas of international health, mental health, and international development at the World Health Organization and Johns Hopkins University. Most recently, he was a Thomas O. Pyle Fellow in Population Medicine at Harvard University (2013-2014) and a Fellow in Pharmaceutical Policy Research at Harvard Medical School and Harvard Pilgrim Health Care Institute (2012-2013), both in Boston, USA.

Huseyin received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the London School of Economics and & Political Science (London, UK); his Master of Public Health Sciences (MSPH) degree in International Health, with a focus on Health Economics from the Johns Hopkins University Bloomberg School of Public Health (Baltimore, MD, USA); and his Bachelor of Arts degree in Biochemistry from Knox College (Galesburg, IL, USA).


Harvard University Thomas O. Pyle Fellowship in Population Medicine (2013-2014)

Harvard Medical School Fellowship in Pharmaceutical Policy Research (2012-2013)

Delta Omega, Alpha Chapter – United States National Honor Society for Public Health (2008)

Cyprus Fulbright Commission – Cyprus-America Scholarship Program Full Recipient (2006-2008)

Merck/American Association for the Advancement of Science (AAAS) Research Award – Undergraduate Research in Biochemistry (2003)

Selected publications

Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol lowering in statin trials|. BMJ. 2014;349:g5741.

Naci H, Ioannidis JPA. How Good Is "Evidence" from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?| Annual Reviews of Pharmacology and Toxicology. 2015;55(1).

Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM. Medication affordability gains following medicare part d are eroding among elderly with multiple chronic conditions|. Health Affairs. 2014;33(8):1435-43.

Naci H, Ioannidis JPA. Comparative Effectiveness of Exercise and Drug Interventions on Mortality Outcomes: Meta-epidemiological Study|. BMJ 2013; 347: f5577.

Naci H, Brugts J, Ades T. Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-analysis of 246,955 Participants from 135 Randomized, Controlled Trials|. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390-9.

Jansen JP, Naci H. Is Network Meta-Analysis as Valid as Standard Pairwise Meta-Analysis? It All Depends on the Distribution of Effect Modifiers|. BMC Med. 2013 Jul 4;11:159.

Mossialos E, Naci H, Courtin E. Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?| Health Policy. 2013 Jul;111(2):135-48.

Naci H, Brugts JJ, Tsoi B, Toor H, Fleurence R, Ades AE. Comparative Benefits of Statins in Primary and Secondary Prevention of All-cause Mortality and Major Coronary Events: A meta-analysis of placebo-controlled and active-comparator trials|. Eur J Prev Cardiol. 2013 Aug;20(4):641-57.

Naci H, Cylus JC, Sato A, Vandoros S, Perampaladas K. Raising the bar for market authorization|. BMJ. 2012;345:e4261. 

Chisholm D, Naci H, Hyder AA, Tran N, Peden M. Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study|. BMJ. 2012; 344: e612.

Sorenson C, Naci H, Cylus JD, Mossialos EA. Evidence of comparative efficacy should have a formal role in European drug approvals|. BMJ 2011; 343: d4849.

Fleurence R, Naci H, Jansen JP. The Critical Role of Observational Evidence in Comparative Effectiveness Research|. Health Affairs. 2010 Oct; 29(10): 1826-1833.